Serum-derived miR-574-5p-containing exosomes contribute to liver fibrosis by activating hepatic stellate cells

Xia Zhou1,2 · Ziyu Liang1 · Shanyu Qin1 · Xianxian Ruan1 · Haixing Jiang1

Received: 29 August 2021 / Accepted: 23 November 2021 / Published online: 29 November 2021

© The Author(s) 2021

Abstract
Aim To investigate the association of serum exosomes miR-574-5p with liver fibrosis, and explore the effect and mechanism of serum exosomes on HSC activation.

Materials and methods Using serum samples collected from healthy adults and patients with liver cirrhosis, we extracted human serum exosomes via ultra-high-speed centrifugation, and co-cultured them with hepatic stellate cells (HSCs) line LX2. LX-2-mediated intake of human serum exosomes was examined by confocal microscopy. To induce liver fibrosis, we administered 20% CCl4 to mice intraperitoneally and adopted an exoEasy MIDI kit to extract serum exosomes. Liver fibrosis-related molecules were determined via qRT-PCR, Western blot, Masson staining, and Immunohistochemical staining.

Results Significantly high miR-574-5p levels were expressed in serum exosomes and were positively correlated with the expression of miR-574-5p, collagen deposition, and α-SMA expression in liver tissues of mice during liver fibrosis. Compared to healthy subjects, serum exosomes from cirrhosis patients were associated with higher expression of miR-574-5p. MiR-574-5p mimic promoted the expression of α-SMA and COL1A1 mRNA and protein in LX-2, whereas miR-574-5p inhibitor exerted no effect.

Conclusion This article demonstrates that miR-574-5p expression in serum exosomes is positively correlated with collagen deposition and HSC activation in liver tissues during liver fibrosis. Serum exosomes potentially activate HSC through the transfer of miR-574-5p to HSC during liver fibrosis.

Keywords Liver fibrosis · Serum exosome · Hepatic stellate cell · miR-574-5p

Introduction
Liver fibrosis occurs due to chronic liver damage and is attributed to multiple predisposing factors, including alcohol consumption, non-alcoholic steatohepatitis (NASH), viral hepatitis, autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), and cholestatic liver disease [1, 2]. Hepatic stellate cell (HSCs) activation is the key event in hepatic fibrosis [3]. Factors, including toxins, hepatitis, steatohepatitis, and autoimmune diseases may trigger the activation of HSCs and transformation into myofibroblasts. Subsequently, the synthesis of extracellular matrix (ECM) promotes the progression of liver fibrosis [4, 5]. Therefore, the regulation of HSCs activation, proliferation, and apoptosis is crucial in the management of liver fibrosis [6].

Exosomes are small vesicles (about 30–150 nm in diameter) secreted by various cells and widely localized in plasma, saliva, urine, and other body fluids [7, 8]. They comprise proteins, lipids, nucleic acids, and other bioactive substances, which influence the progression of diseases via intercellular material and information transduction, or direct action on target cells [9, 10]. miRNAs enriched exosomes are delivered to HSCs [11], which is a crucial event in liver fibrosis. Serum exosomes can be applied in liquid biopsy for noninvasive detection and staging of liver diseases [12, 13]. Recent reports show that normal serum exosomes exhibit anti-fibrotic properties, and contain miRNAs with therapeutic effects against HSCs activation [14].

miRNA, a class of non-coding single-stranded RNA molecules about 22 nucleotides long is encoded by endogenous
genes. It regulates post-transcriptional gene expression, which is an important mechanism for the development of many diseases [15]. Numerous studies have elucidated the mechanisms of miRNA in liver fibrosis [16, 17]. In a previous study, high miR-21 expression in fibrotic liver promoted HSC activation [18, 19]. Simultaneously, miR-29a inhibited collagen synthesis but was lowly expressed when HSC is activated [20]. miR-19b also exerts anti-fibrotic effects in the regulation of the transforming growth factor-β (TGF-β) signaling pathway in HSC [21]. Jeongeun Hyun adopted a miRNA array to analyze the difference of miRNA expression in the process of liver fibrosis in mice and found that miR-574-5p increased most significantly in the fibrosis liver tissue [22]. However, the precise role of miR-574-5p remains unclear. Herein, we analyzed the expression of miR-574-5p in the serum exosomes during liver fibrosis and explored its possible mechanism of action in the process of liver fibrosis.

Material and methods

CCl4-induced hepatic fibrosis in mice

Male C57BL/6 mice (7–8 weeks old) were provided by the experimental animal center of Guangxi Medical University, which we used to develop the liver fibrosis model. To induce liver fibrosis, the mice were intraperitoneally injected with 20% CCl4, 0.4 mL/100 g twice a week. Simultaneously, the control group was administered with the same dose of olive oil. Liver tissue and peripheral blood were collected at 2, 4, 6, and 8 weeks. The perfused liver tissues were fixed with 4% formalin or preserved at—8 °C. We subjected the fixed liver tissues to H&E staining, and then detected collagen via Masson staining. The expression of α-SMA was detected through immunohistochemistry analysis. Serum was separated from peripheral blood for further exosome extraction. Serum EV purification

Human serum samples were centrifuged at low speed (300 g × 15 min 4 °C; 2000 g × 10 min 4 °C) and 10,000 g for 30 min to remove large vesicles. A W41Ti rotor (Beckman Coulter, Brea, CA, USA) was applied to centrifuge the supernatant at 100,000 × g for 90 min. The pellets were washed in phosphate-buffered saline (PBS) to remove protein contaminants and centrifuged again at 100,000 × g for 90 min. The exosomes were resuspended in PBS. 8 μg/ml of serum exosomes from normal adults and cirrhotic patients were co-cultured with LX-2 for 24 h respectively. Total RNA from serum exosomes and LX-2 were extracted by miRNasy Kits (Qiagen) and NucleoZOL(GeneBank). We applied the exoEeasy Midi Kit (Qiagen) to isolate exosomes of mouse serum according to the manufacturer’s instructions. Briefly, 1 volume of buffer was added to 1 volume of the sample. The sample/Buffer XBP was mixed onto the exoEasy spin column and the device spun at 500 g for 1 min. We did another spin at 5000 g for 1 min to eliminate all the liquid. This was followed by the addition of 3.5 ml Buffer XWP and centrifugation at 3000 g for 5 min to remove residual buffer. Exactly 400ul buffer XE was added to elute the exosomes for electron microscopic examination. To extract serum exosomal RNA, 700ul Qiazol was added. The serum exosomes were examined via transmission electron microscopy (TEM). Nanoparticle tracking analysis (NTA) of exosomes was performed using zetaview PMX 110.

Histology

Liver tissue was fixed with formalin, treated by conventional histology, embedded in paraffin, and sectioned (5 μm). Sections were stained with H&E staining (Solarbio, Beijing, China) and Masson trichromatic staining reagent (Bestbio, Shanghai, China) according to standard procedures to assess histopathological severity and collagen deposition in liver tissue. Photographs were captured with a light microscope (Olympus, Tokyo, Japan). Three fields in the section were randomly selected. Collagen was stained blue by Masson staining.
staining. Image J 6.0 software was used to analyze and calculate the collagen deposition area.

**Immunohistochemistry**

Cut paraffin blocks into 5 μm thick slices. The following steps were implemented: routinely dewaxed, dehydration, the antigen was repaired in EDTA buffer for 3 min at high temperature and high pressure, then washed at 25 °C, incubated with 3% hydrogen peroxide for 30 min, washed, and incubated with 5% goat serum at room temperature for 15 min. Then, the sections were incubated with anti-α-SMA (1:250, ab124964, abcam) overnight at 4 °C, incubated with goat anti-rabbit IgG polymers (Zhongshan, Beijing, China) and horseradish enzyme for 30 min in turn at room temperature. Then, counterstained the slices with hematoxylin. The brown granules showing positive expression of α-SMA were observed in liver tissue. At least three magnification fields within the sections were randomly selected with an light microscope (Olympus, Tokyo, Japan), and α-SMA positive areas were calculated with ImageJ 6.0 software.

**HSC cultures and transfection**

LX-2 cells were cultured in DMEM/10% FBS, seeded in 6-well plates, and then cultured in a serum-free medium for the next 24 h. LX-2 cells were treated with serum exosomes of healthy adults and cirrhotic patients for 24 h, respectively. Expressions of collagen α1(I) (COL1A1), α-SMA mRNA, and miR-574-5p were determined via qRT-PCR. miRNA mimic and miRNA inhibitor were transfected using Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen). To detect the expression of collagen α1(I) and α-SMA, we extracted RNA and protein at 24 h and 48 h, respectively. The miRNA-574-5p mimic, nc mimic, miRNA-574-5p inhibitor, and nc inhibitor were purchased from Jima.

**EV binding assays**

The serum exosomes labeled with PKH-67 (20 μg/ml) were added to LX-2 and incubated at 37 °C for 12–24 h in the dark. The cells were washed with PBS and then fixed. We stained the nucleus with DAPI and examined it for fluorescence using a confocal microscope.

**RNA extraction and RT-qPCR**

Total RNA from cultured HSC and liver tissue were extracted by nucleoar (GeneBank) and reverse-transcribed using PrimeScript™ RT Master Mix(TAKARA) following the manufacturer’s protocols. Quantitative real-time RT-PCR was performed using TB Green Premix Ex TaqTM II (TAKARA) with primers for α-SMA, collagen α1(I). Total RNA from serum exosomes and liver tissues were extracted by miRNeasy Micro Kit(Qiagen) and nucleolar (GeneBank) respectively, and then reverse-transcribed using miRcute Plus miRNA First-Strand cDNA Kit (TIANGEN). Quantitative real-time RT-PCR was performed using miRcute Plus miRNA qPCR Kit (TIANGEN). GAPDH (for mRNA) and U6 (for miRNA) acted as the reference gene (Table 1).

**Western blotting**

Protein was isolated through lysis with radioimmunopreparation assay (RIPA) buffer supplemented with 1:100 protease inhibitor (Solarbio, Beijing, China). The BCA protein assay kit (BOSTER, Wuhan, China) was used for protein quantification. Samples were separated by SDS-PAGE gels and transferred onto a PVDF membrane (Millipore). The membranes were blocked for 1 h with 5% skimmed milk and incubated overnight at 4 °C with primary antibodies: anti-C9 (1:1000, ab92726, System Biosciences), anti-TSG101(1:2000, ab125011, System Biosciences), anti-COL1A1(1:2000, ab260043, abcam), anti-α-SMA (1:5000, ab124964, abcam), GAPDH (1:1000, 41,549, CST). Then, after 3 times wash, the membranes were incubated with the HRP-conjugated secondary anti-Rabbit antibody for 1 h at room temperature. Immunoreactive bands were visualized using Immobilon Western HRP (GeneBank; USA) and analyzed in Image J software.

**Statistical analysis**

Masson staining, immunohistochemical staining, and Western-blot results were analyzed by Image J 6.0 software.
Software. The expression levels of miRNAs in exosomes and liver tissues were determined by $2^{-\Delta\Delta CT}$. Data processing and statistical analyses were conducted using SPSS 20.0 software. Data were expressed as mean ± standard deviation. The software GraphPad 8.0 was used for plotting. Comparison of means between the multiple groups was achieved using One-way ANOVA, whereas an independent sample t-test was used for the comparison between the two groups. Spearman correlation coefficient was used for correlation analysis. $P$ < 0.05 denoted statistically significant difference. Each experiment was conducted in three independent replicates.

Results

MiR-574-5p is significantly highly expressed during liver fibrosis

A liver fibrosis model was established through intraperitoneal injection of 20% CCl$_4$ into mice. The liver tissues of each group were subjected to H&E staining. We found that the hepatocytes of the normal group and control group were round or oval, arranged in cords around the central venous area, and distributed radially. No inflammatory cell infiltration or fiber stripe was detected in the portal area. At 2–6 weeks post modeling, there were edema, degeneration, and necrosis of hepatocytes with different degrees of inflammatory cell infiltration, particularly in the portal area. At 8 weeks post modeling, fibrous bands were connected to form fibrous septa. The remaining hepatocytes were separated into multiple pseudo lobular structures; this demonstrated the development of liver cirrhosis (Fig. 1A). Compared to the normal and control groups, Masson staining revealed that the liver of the model group showed different degrees of blue collagen deposition at 2, 4, and 6 weeks, and a larger positive area of collagen deposition; also, the positive area of collagen deposition was significantly larger at 8 weeks ($P$ < 0.001) (Fig. 1B and D). Immunohistochemical results demonstrated a small amount of α-SMA was expressed in the liver tissue of normal and control groups. The positive area of α-SMA expression in the liver tissue of the model group was larger compared to that of normal and control groups at 2, 4, and 6 weeks. α-SMA expression in the liver tissue of the model group at 8 weeks was significantly higher compared to that of normal and control groups ($P$ < 0.001) (Fig. 1C and E). The qRT-PCR results further confirmed that the expression of miR-574-5p in liver tissue of the model group was significantly higher at 4, 6, and 8 weeks compared to that of normal and control groups ($P$ < 0.05) (Fig. 1F).

miR-574-5p is highly expressed in human and mouse serum exosomes during liver fibrosis

Round or oval serum exosomes of human and mice were observed under an electron microscope. NTA detection revealed that the exosomes were about 120 nm in diameter. Westernblot confirmed the expression of CD9 and TSG101 (Fig. 2A–C, E–G). qRT-PCR demonstrated that the expression of miR-574-5p in serum exosomes of patients with liver cirrhosis was significantly higher than that of healthy adults (Fig. 3A). Besides, the expression of miR-574-5p in serum exosomes of mice increased gradually at 2, 4, 6, and 8 weeks during liver fibrosis, and peaked at 8 weeks. The expression of miR-574-5p in serum exosomes of model groups was significantly higher compared to normal and control groups ($P$ < 0.05) (Fig. 3B). Moreover, the expression of miR-574-5p in mouse serum exosomes was positively correlated with HSC activation, collagen deposition, and the expression of miR-574-5p in liver tissues ($P$ < 0.05) (Fig. 3C–E).

Serum exosomes are internalized into HSC

We established the effect of serum exosomes on HSC whereby human serum exosomes were extracted, and co-cultured with human hepatic stellate cell line LX-2. We observed round or oval exosomes under an electron microscope. NTA detection revealed that the exosomes were about 120 nm in diameter. Westernblot confirmed the expression of CD9 and TSG101 (Fig. 2A–C). After PKH67 staining, exosomes co-cultured with LX-2 for over 12 h appeared green around the nucleus (Fig. 2D).

Serum exosomes derived miR-574-5p potentially influence activation of hepatic stellate cells

With the development of liver fibrosis, HSC was activated. Consequently, the expression of miR-574-5p in serum exosomes and liver tissues increased. We co-cultured the serum exosomes from healthy adults and liver cirrhosis patients with HSC for 24 h respectively, and analyzed the expression of miR-574-5p, COL1A1, and α-SMA. The results showed that miR-574-5p expression in HSC co-cultured with serum exosomes of liver cirrhosis patients was higher than that of healthy adults ($P$ < 0.05) (Fig. 3F). Considering the previous results, high miR-574-5p expression was associated with the increase of α-SMA and formation of liver collagen. Also, the expressions of α-SMA and COL1A1 co-cultured with serum exosomes of liver cirrhosis patients were significantly higher compared to that of healthy adults ($P$ < 0.05) (Fig. 3G and H). Based on these results, we speculate that serum exosomes potentially influenced HSC activation by transferring miR-574-5p to HSC.
MiR-574-5p overexpression promotes HSC activation and collagen synthesis

To further elucidate the effect of miR-574-5p on HSCs, we transfected LX-2 with miR-574-5p mimic and miR-574-5p inhibitor, then detected the expression of COL1A1 and α-SMA. Compared to mimic NC, the expressions of COL1A1 and α-SMA mRNA and protein increased significantly in LX2 transfected with miR-574-5p mimic (P < 0.01) (Fig. 4C, E and G), however, miR-574-5p inhibitor had no effect on the expressions of COL1A1 and α-SMA mRNA and protein (P > 0.05) (Fig. 4D, F and G).

Fig. 1 Expression of miR-574-5p in liver tissue during liver fibrosis. A H&E staining of liver tissue. B Masson staining of liver tissue. Collagen deposition areas were stained blue. C Immunohistochemical staining of α-SMA in liver tissue. The brown granules showing positive expression of α-SMA protein were observed in liver tissue. D Histogram of collagen deposition area. E Histogram of α-SMA protein expression. F qRT-PCR detection of miR-574-5p in liver tissue. The column chart showed the comparison of collagen deposition and α-SMA positive area in each group, which was quantified by Image J 6.0 software. *P < 0.05, **P < 0.01, ***P < 0.001 vs normal group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs control group. The ruler is 50 μm (black scale bar). Data represent means ± SD. (n = 3–6). (Color figure online)
Discussion

HSC activation is the central event in liver fibrosis [23]. Exosomes exert a crucial role in the process of HSC activation and liver fibrosis [24]. Herein, we found miR-574-5p was highly expressed in serum exosomes of mouse during liver fibrosis. The expression of miR-574-5p in serum exosomes was positively correlated with HSC activation and collagen deposition. Furthermore, we confirmed that miR-574-5p promotes HSC activation and collagen synthesis, and serum exosomes potentially activate HSC via transferring miR-574-5p to HSC during liver fibrosis.

Liver fibrosis is a common pathological process of sustained injury of liver cells caused by various chronic liver diseases. Following an injury to the liver, HSCs transform into myofibroblast-like cells and synthesize a large amount of extracellular matrix, one of the most important sections associated with liver fibrosis [25]. miRNA, a small (20-24nt) noncoding RNA, blocks mRNA expression through specific interaction with the 3' untranslated regions (UTR) of target gene mRNA [26]. Studies have revealed that various miRNAs are abnormally expressed in the process of liver fibrosis, and they drive the activation, proliferation, and apoptosis of HSCs by regulating various signaling pathways [27, 28]. Jeongeun Hyun performed a miRNA microarray analysis on liver tissues of normal and CCl4 treated mice and revealed that the expression of four miRNAs in the CCl4 treated liver was two times higher compared to the control group. In particular, the expression of miR-574-5p increased significantly [22]. We established a mouse model of liver fibrosis and detected the expressions of miR-574-5p in the liver tissue of the model group increased at 2, 4, 6, and 8 weeks, especially at 8 weeks (P < 0.01). The results were consistent with the literature reports.
The exosome is a small vesicle body of about 30~150 nm in diameter and can be applied as a biological marker to monitor and evaluate the diagnosis and treatment of various liver diseases [29]. Exosomes have an outer lipid membrane and are relatively stable in serum. This explains why serum exosomes can be used for liquid biopsy in non-invasive detection and staging prediction of liver diseases [30]. Meanwhile, the surface of exosomes is rich in specific markers, and while in the serum, they can directly reflect the metabolism of the body, and be applied to evaluate disease progression, treatment, and prognosis [31]. Previous studies found that significantly high levels of miR-574-5p were expressed in liver tissue during the progression of liver fibrosis. Herein, we found that the expression of miR-574-5p in

![Figure 3](https://example.com/figure3.png)

**Fig. 3** A Expressions of miR-574-5p in serum exosomes of patients with cirrhosis and normal healthy adults. B Expressions of miR-574-5p in serum exosomes of mice during liver fibrosis. C Correlation of mouse serum exosome miR-574-5p with expressions of α-SMA protein in mouse liver during liver fibrosis. D Correlation of mouse serum exosome miR-574-5p with collagen deposition in mouse liver during liver fibrosis. E Correlation of mouse serum exosome miR-574-5p with collagen deposition in mouse liver during liver fibrosis. F Expression of miR-574-5p in LX-2. (n=3–6). G Expression of α-SMA mRNA in LX-2. H Expression of COL1A1 mRNA in LX-2. *P<0.05, **P<0.01, ***P<0.001 vs normal group; #P<0.05, ##P<0.01, ###P<0.001 vs control group. Data represent means±SD. (n≥3)
in serum exosomes of patients with liver cirrhosis was significantly higher than that of healthy adults. As liver fibrosis progressed in mice, the expression of miR-574-5p in serum exosomes of model groups was significantly higher than that of normal and control groups at 4, 6, and 8 weeks. Furthermore, the expression level of miR-574-5p in serum exosomes was positively correlated with the expression of HSC activation marker α-SMA, collagen deposition and miR-574-5p in liver tissue.

Serum exosomes can be ingested by HSC. To regulate the process of liver fibrosis, exosomes mainly act as the carrier of intercellular signal transmission [13]. Studies have revealed that normal mouse serum exosomes can inhibit HSC proliferation and the expression of fibrosis-related molecules, and alleviate liver fibrosis in mice [14]. In the present study, we used PKH67 to label human serum exosomes and found that human serum exosomes were engulfed by human hepatic stellate cell line LX-2. Also, the expressions of α-SMA and COL1A1 in LX-2 co-cultured with normal serum exosomes were significantly lower than that in LX2 co-cultured with cirrhotic serum exosomes (P < 0.05). The expression of miR-574-5p in LX-2 co-cultured with cirrhosis serum exosomes was significantly higher compared to that in LX-2 co-cultured with normal serum exosomes. We speculated that cirrhosis serum exosomes may promote fibrosis through the transfer of miR-574-5p to LX-2.

Previous studies have shown that miR-574-5p is related to proliferation and migration of tumor cells, miR-574-5p promotes cell proliferation and migration [32, 33]. Elsewhere, The effect of miR-574-5p in fibrotic diseases are rarely reported. Kenneth M. Sterling showed that two of the mouse COL3A1 first intron expressed sequence tags (EST)’s

---

![Figure 4](image.png)

**Fig. 4** Effect of miR-574-5p on the expression of COL1A1 and α-SMA in LX-2. A Expression of miR-574-5p in LX-2 transfected with miR-574-5p mimic and miR-574-5p inhibitor. B Expression of COL1A1 mRNA in LX-2 transfected with miR-574-5p mimic and miR-574-5p inhibitor. C Expression of α-SMA mRNA in LX-2 transfected with miR-574-5p mimic and miR-574-5p inhibitor. D Expression of α-SMA mRNA in LX-2 transfected with miR-574-5p mimic and miR-574-5p inhibitor. E Expression of COL1A1 and α-SMA protein in LX-2 transfected with miR-574-5p mimic and miR-574-5p inhibitor. *P < 0.05, **P < 0.01, ***P < 0.001 vs nc group. ns: no significance. Data represent means ± SD. (n ≥ 3)
have significant identity to mmu-miR-466f-3p and mmu-miR574-5p, the predicted targets of mmu-miR-466f-3p include COL1A1, COL19A1, COL11A2, COL4A1, and COL4A5, indicating that COL3A1 intronic miRNA, such as mmu-miR574-5p may regulate the expression of collagen genes [34]. Recent years, it has been found that miR-574-5p is involved in fibroblast differentiation and collagen synthesis. Juncui found that TGF-β stimulated the expression of miR-574-5p in human cardiac fibroblasts. ARID3A is a DNA conjugation protein that negatively regulates tumor cell metastasis and invasion. MiR-574-5p promotes cardiac fibroblast proliferation and differentiation by targetting mRNA and protein levels of ARID3A [35]. However, there is no report on the role of miR-574-5p in liver fibrosis. Herein, we transfected LX-2 with miR-574-5p mimic and miR-574-5p inhibitor and found that miR-574-5p could promote the expression of α-SMA and COL1A1 in LX-2. But, inhibition of miR-574-5p exerted no effect on the expression of α-SMA and COL1A1. Our research demonstrated that miR-574-5p inhibitor had no effect on LX-2, as Jun Cui reported miR-574-5p can mediate TGF-β-induced human cardiac fibroblasts differentiation, we speculated that due to competitive inhibition, miR-574-5p couldn’t exert inhibitory effects, secondly, miR-574-5p may exert its inhibitory function under the action of TGF-β. In brief, these findings demonstrated that the expression of serum exosome miR-574-5p was significantly elevated during the progression of liver fibrosis. Consequently, serum exosome may activate HSC and promote liver fibrosis through the transfer of miR-574-5p to HSC.

Conclusion

The present study demonstrates that the expression of serum exosome miR-574-5p is closely related to liver fibrosis. Serum exosome miR-574-5p promotes HSC activation and collagen synthesis and may be adopted as a serum marker for liver fibrosis. Thus, miR-574-5p could serve as a novel therapeutic target in liver fibrosis.

Acknowledgements This work was supported in part by Key laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education, Talent Highland of Innovation Team for Diagnosis and Treatment of Chronic Liver Disease Laboratory, and Research Institute of Innovative Think-tank in Guangxi Medical University (The gene-environment interaction in hepatocarcinogenesis in Guangxi HCCs and its translational applications in the HCC prevention).

Author contributions All authors contributed to the study conception and design, data collection and analysis. XZ: Writing—original draft. Visualization. ZL: Data Investigation. XR: Methodology. Software. SQ: Supervision, Conceptualization. HJ: Funding acquisition, Project administration, Writing—review & editing.

Funding This work was funded by the National Natural Science Foundation of China (81960119) and Natural Science Foundation of Guangxi Province (2018GXNSFAA281221).

Data availability The authors declare that all data supporting the conclusion of this study are available in the article.

Declarations

Conflict of interest Authors declare that there is no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethics committee of the First Affiliated Hospital of Guangxi Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Medical Ethics Committee of First Affiliated Hospital of Guangxi Medical University has approved the protocol.

Consent to participate Informed consent was obtained from all individual participants included in the study.

Consent for publication All of the authors consent for publication.

Animal rights Animal ethics review follows the Guiding Opinions on the Treatment of Laboratory Animals issued by the Ministry of Science and Technology of the People’s Republic of China and the Laboratory Animal Guideline for Ethical Review of Animal Welfare issued by the National Standard GB/T35892-2018 of the People’s Republic of China.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Parola M, Pinzani M (2019) Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37–55
2. Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18(3):151–166
3. Higashi T, Friedman SL, Hoshida Y (2017) Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 121:27–42
4. Berumen J, Baglieri J, Kisseleva T, et al (2021) Liver fibrosis: pathophysiology and clinical implications. Wiley interdisciplinary reviews. Syst Biol Med 13(1): e1499.
5. Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7):397–411
6. Roehlen N, Crouchet E, Baumert TF (2020) Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 9(4):875
7. Doyle LM, Wang MZ (2019) Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 8(7):1277
8. Hessvik NP, Llorente A (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci CMLS 75(2):193–208
9. Das CK, Jena BC, Banerjee I et al (2019) Exosome as a novel shuttle for delivery of therapeutics across biological barriers. Mol Pharm 16(1):24–40
10. Li S-P, Lin Z-X, Jiang X-Y et al (2019) Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. Acta Pharmacol Sin 39(4):542–551
11. Iacob DG, Rosca A, Ruta SM (2020) Circulating microRNAs as non-invasive biomarkers for hepatitis B virus liver fibrosis. World J Gastroenterol 26(11):1113–1127
12. Thietart S, Rautou P-E (2020) Extracellular vesicles as biomarkers in liver diseases: a clinician’s point of view. J Hepatol 73(6):1507–1525
13. Bruno S, Chiabotto G, Camussi G (2020) Extracellular vesicles: a therapeutic option for liver fibrosis. Int J Mol Sci 21(12):4255
14. Chen L, Chen R, Kemper S et al (2018) Therapeutic effects of serum extracellular vesicles in liver fibrosis. J Extracell Vesicles 7(1):1461505
15. Wang X, He Y, Mackowiak B et al (2021) MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 70(4):784–795
16. Ezhilarasan D (2020) MicroRNA interplay between hepatic stellate cell quiescence and activation. Eur J Pharmacol 885:173507
17. Zehra M, Curry JC, Pillai SS et al (2020) Elucidating potential profibrotic mechanisms of emerging biomarkers for early prognosis of hepatic fibrosis. Int J Mol Sci 21(13):4737
18. Wu K, Ye C, Lin L, et al (2016) Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. Clin Sci (London, England : 1979) 130(16):1469–1480.
19. Huang Q, Zhang X, Bai F et al (2019) Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways. Int Immunopharmacol 66:41–51
20. Knabel MK, Ramachandran K, Karhadkar S, et al (2015) Systemic delivery of scAAV8-encoded MiR-29a ameliorates hepatic fibrosis in carbon tetrachloride-treated mice. PloS One 10(4): e0124411.
21. Brandon-Warner E, Benbow JH, Swet JH et al (2018) Adenovirus-associated virus serotype 2 vector-mediated reintroduction of microRNA-1-9b attenuates hepatic fibrosis. Hum Gene Ther 29(6):674–686
22. Hyun J, Park J, Wang S et al (2016) MicroRNA expression profiling in CCl4-induced liver fibrosis of mus musculus. Int J Mol Sci 17(6):961
23. Dewidar B, Meyer C, Dooley S, et al (2019) TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells 8(11):1419.
24. Bruno S, Chiabotto G and Camussi G (2020) Extracellular vesicles: a therapeutic option for liver fibrosis. Int J Mol Sci 21(12):4255.
25. Roehlen N, Crouchet E and Baumert TF (2020) Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 9(4):875.
26. Lu TX, Rothenberg ME (2018) MicroRNA. J Allergy Clin Immunol 141(4):1202–1207
27. Su Q, Kumar V, Sud N et al (2018) MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev 129:54–63
28. Chen Q, Zhang J, Zheng T et al (2019) The role of microRNAs in the pathogenesis, grading and treatment of hepatic fibrosis in schistosomiasis. Parasit Vectors 12(1):611
29. Yu X, Odenthal M, Fries JWU (2016) Exosomes as miRNA carriers: formation-function-future. Int J Mol Sci 17(12):2028
30. Shen J, Huang C-K, Yu H et al (2017) The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. J Cell Mol Med 21(5):986–992
31. Cai P, Mu Y, Olveda RM et al (2020) Serum exosomal miRNAs for grading hepatic fibrosis due to schistosomiasis. Int J Mol Sci 21(10):3560
32. Zhang M, Song Y (2019) LncRNA PTCSC3 suppressed cervical carcinoma cell invasion and proliferation via regulating miR-574-5p. Am J Transl Res 11(11):7186–7194.
33. Yu G, Xiong D, Liu Z, Li Y, Chen K, Tang H (2019) Long non-coding RNA LINC00052 inhibits colorectal cancer metastasis by sponging microRNA-574-5p to modulate CALCOCO1 expression. J Cell Biochem 120(10):17258–17272
34. Kenneth M Sterling (2011) The procollagen type III, alpha1(COL3A1) gene first intron expresses poly-A+ RNA corresponding to multiple ESTs and putative miRNAs. J Cell Biochem 112(2):541–547.
35. Cui J, Qi S, Liao R et al (2020) MiR-574-5p promotes the differentiation of human cardiac fibroblasts via regulating ARID3A. Biochem Biophys Res Commun 521(2):427–433